Cargando…
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
[Image: see text] The pandemic caused by SARS-CoV-2 is currently representing a major health and economic threat to humanity. So far, no specific treatment to this viral infection has been developed and the emergency still requires an efficient intervention. In this work, we used virtual screening t...
Autores principales: | Maffucci, Irene, Contini, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640956/ https://www.ncbi.nlm.nih.gov/pubmed/32893632 http://dx.doi.org/10.1021/acs.jproteome.0c00383 |
Ejemplares similares
-
In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
por: Wei, Tian-zi, et al.
Publicado: (2020) -
Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020) -
Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: In silico study
por: Kurniawan, Entuy, et al.
Publicado: (2021) -
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021) -
In silico targeting SARS-CoV-2 spike protein and main protease by biochemical compounds
por: Babaeekhou, Laleh, et al.
Publicado: (2021)